Nilanjan Adhikari

Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors

Goverdhan Lanka, Darakhshan Begum, Suvankar Banerjee et al. · Computers in Biology and Medicine · 2023 · 98 citations

Medicinal Chemistry, Virtual Screening, Silico Perspective +13

Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects

Prakruti Trivedi, Nilanjan Adhikari, Sk. Abdul Amin et al. · European Journal of Pharmaceutical Sciences · 2018 · 59 citations

Combinatorial Chemistry, Medicinal Chemistry, Biochemistry +11

Exploring pyrazolo[3,4-<i>d</i>]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: a predictive approach combining comparative validated multiple molecular modelling techniques

Sk. Abdul Amin, Sonam Bhargava, Nilanjan Adhikari et al. · Journal of Biomolecular Structure and Dynamics · 2017 · 56 citations

Drug Target, Chemical Biology, Higher Inhibitory Activity +17

Small molecule drug conjugates (SMDCs): an emerging strategy for anticancer drug design and discovery

Tarun Patel, Nilanjan Adhikari, Sk. Abdul Amin et al. · New Journal of Chemistry · 2021 · 56 citations

Drug Target, Tumor Biology, Nanomedicine +18

Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays

Nilanjan Adhikari, Amit Kumar Halder, Sumana Mallick et al. · Bioorganic & Medicinal Chemistry · 2016 · 53 citations · Full text

Medicinal Chemistry, Hit Identification, Biochemistry +10